Patients taking certolizumab pegol are twice as likely to achieve ACR20 compared to placebo
A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint ...
Jun 7, 2012
0
0